A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1
217
about 4 years
18+
8 sites in CA, CT, FL +4
About this study
This trial is testing the safety and dosing of BGB-26808 alone or with tislelizumab in people with advanced solid tumors. The goal is to determine the best dose for BGB-26808.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BGB-26808
- 2.Take Chemotherapy
- 3.Take Tislelizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
tislelizumab
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-26808, Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Phase 1a and 1b: Disease Control Rate (DCR), Phase 1a and 1b: Duration of Response (DOR), Phase 1a: Apparent clearance (CL/F) for BGB-26808, Phase 1a: Area under the concentration-time curve (AUC) for BGB-26808, Phase 1a: Half-life (t1/2) for BGB-26808, Phase 1a: Maximum observed plasma concentration (Cmax) for BGB-26808, Phase 1a: ORR, Phase 1a: Time to maximum plasma concentration (Tmax) for BGB-26808
Oncology